Publikationen

1. Afshar-Oromieh,A., Babich,JW., Kratochwil,C., Giesel,FL., Eisenhut,M., Kopka,K., Haberkorn,U.: The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. Journal of Nuclear Medicine 57 (Suppl 3), 79S-89S, 2016

2. Afshar-Oromieh,A., Hetzheim,H., Kuebler,W., Kratochwil,C., Giesel,FL., Hope,TA., Eder,M., Eisenhut,M., Kopka,K., Haberkorn,U.: Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. European Journal of Nuclear Medicine and Molecular Imaging 43 (9), 1611-1620, 2016

3. Bender,C., Dimitrakopoulou-Strauss,A., Enk,A., Hassel,JC.: Safety of the PD-1 antibody Pembrolizumab in patients with high-grade adverse events under ipilimumab treatment. Annals of Oncology 27 (7), 1353-1354, 2016

4. Benesova,M., Bauder-Wuest,U., Schaefer,M., Klika,K.D., Mier,W., Haberkorn,U., Kopka,K., Eder,M.: Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. Journal of Medicinal Chemistry 59 (5), 1761-1775, 2016

5. Breki,C.M., Dimitrakopoulou-Strauss,A., Hassel,J., Theoharis,T., Sachpekidis,C., Pan,L., Provata,A.: Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab. European Journal of Nuclear Medicine and Molecular Imaging 6 (1), 61, 2016

6. Cieciera,M., Kratochwil,C., Moltz,J., Kauczor,H.U., Holland-Letz,T., Choyke,P., Mier,W., Haberkorn,U., Giesel,F.L.: Semi-automatic 3D-volumetry of liver metastases from neuroendocrine tumors to improve combination therapy with 177Lu-DOTATOC and 90Y-DOTATOC. Diagnostic and Interventional Radiology 22 (3), 201-206, 2016

7. Delker,A., Fendler,W.P., Kratochwil,C., Brunegraf,A., Gosewisch,A., Gildehaus,F.J., Tritschler,S., Stief,C.G., Kopka,K., Haberkorn,U., Bartenstein,P., Boening,G.: Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 43 (1), 42-51, 2016

8. Dick,J., Lang,N., Slynko,A., Kopp-Schneider,A., Schulz,C., Dimitrakopoulou-Strauss,A., Enk,A.H., Hassel,J.C.: Use of LDH and autoimmune side effects to predict response to ipilimumab treatment. Immunotherapy 8 (9), 1033-1044, 2016

9. Flechsig,P., Kratochwil,C., Warth,A., Rath,D., Eichwald,V., Huber,P.E., Kauczor,H.U., Haberkorn,U., Giesel,F.L.: A Comparison of microCT and microPET for Evaluating Lymph Node Metastasis in a Rat Model. Molecular Imaging and Biology 18 (2), 243-248, 2016.

10. Flechsig,P., Choyke,P., Kratochwil,C., Warth,A., Antoch,G., Holland-Letz,T., Rath,D., Eichwald,V., Huber,P.E., Kauczor,H.U., Haberkorn,U., Giesel,F.L.: Increased x-ray attenuation in malignant vs. benign mediastinal nodes in an orthotopic model of lung cancer. Diagnostic and Interventional Radiology 22 (1), 35-39, 2016

11. Freitag,M.T., Radtke,J.P., Hadaschik,B.A., Kopp-Schneider,A., Eder,M., Kopka,K., Haberkorn,U., Roethke,M., Schlemmer,H.P., Afshar-Oromieh,A.: Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 43 (1), 70-83, 2016

12. Giesel,F.L., Cardinale,J., Schaefer,M., Neels,O., Benesova,M., Mier,W., Haberkorn,U., Kopka,K., Kratochwil,C.: F-18-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging 43 (10), 1929-1930, 2016

13. Giesel,F.L., Sterzing,F., Schlemmer,H.P., Holland-Letz,T., Mier,W., Rius,M., Afshar-Oromieh,A., Kopka,K., Debus,J., Haberkorn,U., Kratochwil,C.: Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 43 (8), 1400-1406, 2016

14. Haberkorn,U., Eder,M., Kopka,K., Babich,J.W., Eisenhut,M.: New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. Clinical Cancer Research 22 (1), 9-15, 2016

15. Haberkorn,U., Kopka,K., Hadaschik,B.: Positron Emission Tomography-computed Tomography with Prostate-specific Membrane Antigen Ligands as a Promising Tool for Imaging of Prostate Cancer. European Urology 69 (3), 397-399, 2016

16. Hassel,J.C., Lee,S.B., Meiss,F., Meier,F., Dimitrakopoulou-Strauss,A., Jaeger,D., Enk,A.H.: Vemurafenib and Impilimumab: a promising combination? Results of a case series. OncoImmunology 5 (4), e1101207, 2016

16. Heußer,T., Rank,C.M., Freitag M.T., Dimitrakopoulou-Strauss,A., Schlemmer, H.-P., Beyer,T., Kachelrieß,M.: MR-consistent simultaneous reconstruction of attenuation and activity distributions to clinical non-TOF PET/MR. IEEE Transactions on Nuclear Science 63 (5), 2443-2451, 2016.

17. Kratochwil,C., Afshar-Oromieh,A., Kopka,K., Haberkorn,U., Giesel,FL.: Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.. Seminars in Nuclear Medicine 46 (5), 405-418, 2016

18. Kratochwil,C., Bruchertseifer,F., Giesel,FL., Weis,M., Verburg,FA., Mottaghy,F., Kopka,K., Apostolidis,C., Haberkorn,U., Morgenstern,A.: 225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine 57 (12), 1941-1944, 2016

19. Kratochwil,C., Giesel,FL., Stefanova,M., Benesova,M., Bronzel,M., Afshar-Oromieh,A., Mier,W., Eder,M., Kopka,K., Haberkorn,U.: PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.  Journal of Nuclear Medicine 57 (8), 1170-1176, 2016

20. Liolios,C., Schaefer,M., Haberkorn,U., Eder,M., Kopka,K.: Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer. Bioconjugate Chemistry 27 (3), 737-751, 2016

21. Liolios,C., Schaefer,M., Haberkorn,U., Eder,M., Kopka,K.: Correction to Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer. Bioconjugate Chemistry 27 (7), 1770-1770, 2016

22. Ronellenfitsch,U., Dimitrakopoulou-Strauss,A., Jakob,J., Kasper,B., Nowak,K., Pilz,LR., Attenberger,U., Gaiser,T., Egerer,G., Froehling,S., Derigs,HG., Schwarzbach,M., Hohenberger,P.: Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS). BMJ open 6 (1), e009558, 2016

23. Ronellenfitsch,U., Henzler,T., Menge,F., Dimitrakopoulou-Strauss,A., Hohenberger,P.: [Advanced gastrointestinal stromal tumors : What role does surgery currently play in multimodal concepts?]. Chirurg 87 (5), 389-397, 2016

24. Sachpekidis,C., Eder,M., Kopka,K., Mier,W., Hadaschik,BA., Haberkorn,U., Dimitrakopoulou-Strauss,A.: (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 43 (7), 1288-1299, 2016

25. Sachpekidis,C., Hassel,J.C., Dimitrakopoulou-Strauss,A.: 18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab. Clinical Nuclear Medicine 41 (2), 156-158, 2016

26. Sachpekidis,C., Kopka,K., Eder,M., Hadaschik,BA,, Freitag.MT., Pan,L., Haberkorn,U., Dimitrakopoulou-Strauss,A.: 68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer. Clinical Nuclear Medicine 41 (11), e473-e479, 2016

27. Sterzing,F., Kratochwil,C., Fiedler,H., Katayama,S., Habl,G., Kopka,K., Afshar-Oromieh,A., Debus,J., Haberkorn,U., Giesel,F.: 68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging 43 (1), 34-41, 2016

28. Weber,T., Boetticher,B., Arndt,MA., Mier,W., Sauter,M., Exner,E., Keller,A., Kramer,S., Leotta,K., Wischnjow,A., Grosse-Hovest,L., Strumberg,D., Jaeger,D., Groene,HJ., Haberkorn,U., Brem,G., Krauss,J.: Preclinical evaluation of a diabody-based 177Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model. Cancer Letters 381 (2), 296-304, 2016

29. Weber,T., Boetticher,B., Mier,W., Sauter,M., Kraemer,S., Leotta,K., Keller,A., Schlegelmilch,A., Grosse-Hovest,L., Jaeger,D., Haberkorn,U., Arndt,M.A., Krauss,J.: High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab. European Journal of Nuclear Medicine and Molecular Imaging 43 (3), 489-498, 2016

30. Wuestemann,T., Bauder-Wuest,U., Schaefer,M., Eder,M., Benesova,M., Leotta,K., Kratochwil,C., Haberkorn,U., Kopka,K., Mier,W.: Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals. Theranostics 6 (8), 1085-1095, 2016

31. Zamagni,E., Nanni,C., Gay,F., Pezzi,A., Patriarca,F., Bellò,M., Rambaldi,I., Tacchetti,P., Hillengass,J., Gamberi,B., Pantani,L., Magarotto,V., Versari,A., Offidani,M., Zannetti,B., Carobolante,F., Balma,M., Musto,P., Rensi,M., Mancuso,K., Dimitrakopoulou-Strauss,A., Chauviè,S., Rocchi,S., Fard,N., Marzocchi,G., Storto,G., Ghedini,P., Palumbo,A., Fanti,S., Cavo,M.: 18F-FDG PET/CT FOCAL, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia 30 (2), 417-422

nach oben
powered by webEdition CMS